首页> 外国专利> CANCER THERAPY BY COMBINATION USE OF ONCOLYTIC VACCINIA VIRUS AND IMMUNE CHECKPOINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINATION MEDICINE FOR USE IN THE CANCER THERAPY

CANCER THERAPY BY COMBINATION USE OF ONCOLYTIC VACCINIA VIRUS AND IMMUNE CHECKPOINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINATION MEDICINE FOR USE IN THE CANCER THERAPY

机译:癌症治疗通过组合使用溶瘤痘苗病毒和免疫检查点抑制剂,以及用于癌症治疗的药物组合物和组合药物

摘要

The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.
机译:本发明提供了遗传修饰的痘苗病毒(特别是溶血性痘苗病毒)的联合治疗和用于治疗癌症的另一种癌症治疗,以及用于治疗的药物组合物和组合试剂盒。 更具体地,本发明提供了含有编码白细胞蛋白-7(IL-7)的多核苷酸的痘苗病毒的治疗和编码白细胞蛋白-12(IL-12)的多核苷酸,以及免疫检查点抑制剂和药物组合物和组合 用于治疗的套件。

著录项

  • 公开/公告号US2021315951A1

    专利类型

  • 公开/公告日2021-10-14

    原文格式PDF

  • 申请/专利权人 ASTELLAS PHARMA INC.;

    申请/专利号US201917279937

  • 发明设计人 SHINSUKE NAKAO;TATSUYA KAWASE;

    申请日2019-09-25

  • 分类号A61K35/768;A61P35;A61K38/20;C12N7;A61K39/395;A61P35/04;

  • 国家 US

  • 入库时间 2022-08-24 21:41:07

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号